# FITing a BIT of Consumer-Based Technology Into Patient Management

18

rage Age

196.6

159.1

Children's Hospital of Philadelphia Cardiac Center

Anshul Ramanathan, BS, David Goldberg, MD, Catherine Avitabile, MD



#### Background

Many single ventricle congenital heart diseases are palliated through a set of surgeries, ending in the Fontan procedure. Regular exercise can improve exercise capacity and is increasingly recognized as safe in this population. With the increasing popularity of consumer-based activity monitors such as "Fitbit", it is important to explore the idea that giving patients a device is a way to get them engaged in exercise and monitor heart activity from an outpatient management standpoint.

#### Methods

We prospectively studied the compliance with Fitbit activity monitoring in a cohort of 19 prospectively enrolled adolescents after Fontan palliation. Subjects were seen in clinic between November 2018 and April 2019 and received a Fitbit Blaze device which was to be worn as continuously as possible for 3 months. Fitbit-wearing compliance was measured by looking at daily resting heart rate data. At the completion of the 3 months, subjects were asked to complete a questionnaire to evaluate their acceptance of the devices and to gauge their interest in using technology to augment their outpatient medical care.

# Technology

The devices were set up to synch automatically and wirelessly to a computer or smartphone using Bluetooth technology. Data was reviewed and monitored frequently through the "fitabase" data platform which depicted the study participants' resting heart rate, pule, oxygen saturations.

The study will examine if adolescents who have
undergone the Fontan operation will accept the use
of activity monitors on a daily basis and whether or
not these devices provide meaningful data.

Objectives

The primary objective is to see if using activity monitors would be feasible in the outpatient management of Fontan patients

The secondary objective is to asses the acceptability of integrating technology into patient care

Schedule of Study Procedures							
Study Phase	Screening	Initial Study Visit	Study Completion Visit				
Visit Number		1	2				
Review of medical records to determine eligibility for study enrolment	х						
nformed Consent/Assent		х					
Physical Examination		х	X				
Vital Signs: BP, HR, RR		X*	X				
Height and Weight		X*	X				
Set Up and Disperse Activity Monitors		X*					
Demographic data collection		X*					
Questionnaire completion			X				

1

Participant PID:

Cardiac diagnosis

Date of birth

Medications

Co-morbidities

Weight/Height/BMI

Echocardiographic data

Date of Fontan and type of

Gender

Race

### **Demographic Data and Questionnaire**

	an of the second	Sento April	- april	CHOUTHER	Compre	Disagree
	I enjeyed wearing the Fithit device.	'	2	,	4	'
	The Fidst device was easy to use.	1	2	,	*	5
	I was more active than awaid when wearing the mension.	1	2	,	4	,
	Wearing the monitor made me find antious.	1	2	,		*
	I will continue to use the monitor now that the study is over.	1	2	,	4	,
	I am interorted in using a smart phone application to commutatore with my cardiologist.	1	2	3	4	5
Fontan	I am innerced in using a smart plone application to transmit activity data to my	1	2	3	4	5

			Results		
100	Participant	Compliance Data		Patient number 1 2	% complian 93.54% 58.06%
90				3 4	63.44% 68.81%
20				5	12.08% 3.29%
ω				7	31.87% 24.18%
so				10	16.48%
20		_		11 12 13	59.34% 3.30%
20		. 11 1.		13 14 15	7.69%
0 1 2 2 0	s s 7 a Par	9 10 11 12 13 1 rticipant number	8 15 16 17 18 19	16 17 18	5.56% 88.89% 27.96%
				19	4.30%
Patient Number	Height	Weight	Date of Consent	19 FUEL or Not FUEL	4.30% Gender
Patient Number	Height 160	Weight 50.8	Date of Consent 11/8/18	19 FUEL or Not FUEL FUEL	4.30% Gender Female
Patient Number 1 2	Height 160 170.2	Weight 50.8 61.7 2(12/00	Date of Consent 11/8/18 11/12/18 11/12/18	19 FUEL or Not FUEL FUEL FUEL	4.30% Gender Female Male
Patient Number 1 2 3	Height 160 170.2 6/23/00	Weight 50.8 61.7 3/12/00	Date of Consent 11/8/18 11/12/18 11/16/18 11/20/18	19 FUEL or Not FUEL FUEL FUEL FUEL	4.30% Gender Female Male Male
Patient Number 1 2 3 4 5	Height 160 170.2 6/23/00 166 171.6	Weight 50.8 61.7 3/12/00 44.9 52.9	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL	4.30% Gender Female Male Male Male
Patient Number 1 2 3 4 5 6	Height 160 170.2 6/23/00 166 171.6 159	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18 12/6/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL FUEL FUEL FUEL	4.30% Gender Female Male Male Male Male
Patient Number 1 2 3 4 5 6 7	Height 160 170.2 6/23/00 166 171.6 159 145	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 47.1	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18 12/7/18 12/7/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL FUEL FUEL Not FUEL	4.30% Gender Female Male Male Male Male Male
Patient Number 1 2 3 4 5 6 7 8	Height 160 170.2 6/23/00 166 171.6 159 145 155	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 47.1 47.7	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18 12/13/18 12/13/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL Not FUEL Not FUEL	4.30% Gender Female Male Male Male Female Female
Patient Number 1 2 3 4 5 6 7 8 9	Height 160 170.2 6/23/00 166 171.6 159 145 155 172	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 47.1 47.7 50.8	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18 12/7/18 12/13/18 12/13/18 12/20/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL FUEL Not FUEL Not FUEL Not FUEL	4.30% Gender Female Male Male Male Female Female Female Male
Patient Number 1 2 3 4 5 6 7 8 9 10	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1	Weight   50.8   61.7   3/12/00   44.9   53.9   44.9   47.1   47.7   50.8   53.9	Date of Consent 11/8/18 11/12/18 11/16/18 11/30/18 12/6/18 12/7/18 12/13/18 12/13/18 12/20/18 12/27/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL FUEL Not FUEL Not FUEL Not FUEL	4.30% Gender Female Male Male Male Female Female Female Female
Patient Number 1 2 3 4 5 6 7 8 9 10 11	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1 173.5	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 47.1 47.7 50.8 53.9 60.7	Date of Consent 11/8/18 11/12/18 11/10/18 12/6/18 12/7/18 12/13/18 12/20/18 12/20/18 12/27/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL NOT FUEL NOT FUEL FUEL	4.30% Gender Female Male Male Male Female Female Female Female Female Male
Patient Number 1 2 3 4 5 6 7 8 9 10 11 12	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1 173.5 169.9	Weight   50.8   61.7   3/12/00   44.9   53.9   44.9   57.1   47.7   50.8   53.9   60.7   54	Date of Consent 11/8/18 11/12/18 11/16/18 12/6/18 12/718 12/718 12/13/18 12/13/18 12/20/18 12/28/18 12/28/18 12/28/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL FUEL Not FUEL Not FUEL Not FUEL FUEL Not FUEL Not FUEL FUEL	4.30% Gender Female Male Male Male Female Female Female Female Female Female
Patient Number 1 2 3 4 5 6 7 8 9 10 11 12 13	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1 173.5 169.9 142.5	Weight   50.8   61.7   3/12/00   44.9   53.9   47.1   47.7   50.8   53.9   60.7   54   36.2	Date of Consent 11/8/18 11/12/18 11/12/18 11/30/18 12/7/18 12/13/18 12/18/18 12/20/18 12/20/18 12/28/18 12/28/18 12/28/18	19 FUEL or Not FUEL FUEL FUEL FUEL FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL	4.30% Gender Female Male Male Male Female Female Female Female Female Female Female Female Male
Patient Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14	Height 160 170.2 6/23/00 166 171.6 159 145 172 165.1 173.5 169.9 142.5 140	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 47.1 47.7 50.8 53.9 60.7 54 36.2 30.1	Date of Consent 11/8/18 11/12/18 11/16/18 12/6/18 12/7/18 12/18/18 12/18/18 12/20/18 12/27/18 12/27/18 12/27/18 12/27/18 13/19 1/3/19 1/3/19 1/2/4/19	19 FUEL of NOT FUEL FUEL FUEL FUEL FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL	4.30% Gender Male Male Male Male Female Female Female Male Female Male Male
Patient Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1 173.5 169.9 142.5 140 166.4	Weight 50.8 61.7 3/12/00 44.9 53.9 44.9 44.9 44.9 44.9 44.7 50.8 53.9 60.7 54 36.2 30.1 49.8	Date of Consent 11/8/18 11/16/18 11/16/18 12/6/18 12/13/18 12/13/18 12/13/18 12/20/18 12/27/18 12/27/18 12/27/18 12/28/18 12/24/19 1/3/19	19 FUEL or Noti FUEL FUEL FUEL FUEL FUEL FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL Not FUEL	4.30% Gender Female Male Male Male Female Female Male Female Male Female Male Male Male Male
Patient Number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	Height 160 170.2 6/23/00 166 171.6 159 145 155 172 165.1 173.5 169.9 142.5 140 166.4 157.8	Weight 50.8 61.7 3)12/00 44.9 53.9 44.9 47.7 53.9 60.7 53.9 60.7 54 36.2 30.1 49.8 48.6	Date of Consect. 11/6/18 11/12/18 11/16/18 11/30/18 12/6/18 12/718 12/13/18 12/70/18 12/70/18 12/70/18 12/70/18 12/70/18 12/70/19 1/30/19 1/30/19 1/31/19 1/31/19	19 FUEL of NOT FUEL FUEL FUEL FUEL FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL NOT FUEL FUEL FUEL FUEL	4.30% Gender Female Male Male Male Female Female Female Male Female Male Male Male Female Female

3/1/19

4/18/19

FUEL

PERCENTAGE OF PARTICIPANTS IN AN 15 (σ = 1.66) CONCOMITANT EXCERSIZE-RELATED STUDY 51.78 (σ = FUEL 9.9) 163.6 cm (σ = 26% 10.5% tinuous Participation npliance > 75%) 52.6% 47.4%

68.3

54.3

FUEL was an adjacent study under a different PI and study coordinator that also involved an exercise component. Many participants who were enrolled in FLIFL also chose to enroll in this Fitbit study. FUEL provided its participants with a more regimented and personalized exercise plan which seemed to generally (but not always) correlate with better compliance in the Fitbit monitor study.

Female

# Conclusion

Unprompted compliance with a Fitbit activity monitor in a cohort of adolescent patients after Fontan was quite poor. While ambulatory monitoring may be a useful adjunct to exercise training programs, the mere presence of the device does not appear to be sufficient to motivate this cohort to be compliant, at least without prompting. Perhaps if a Fitbit was given to Fontan subjects, it would be beneficial if it were tied to another training program. More work is needed to understand the role of ambulatory activity monitors in comprehensive wellness programs for this cohort of patients.

## Future Plans

Further study should include an exercise regimen or training program in conjunction with the FitBit to improve compliance and thereby become a more realistic tool in the outpatient management of Fontan patients. Future studies should also aim to understand the importance of goals, feedback and incentives to affect behavioral change with behavioral devices. Finally, future studies should also aim to receive feedback from all participants.

#### Acknowledgments

Supported in part by the Cardiac Center at the Children's Hospital of Philadelphia.

Special thanks to David Goldberg, MD for acting as Principal Investigator and Catherine Avitabile, MD, for her guidance and support

**Contact Information** 

Anshul Ramanathan, BS

T: 215-410-9199

anshul.ramanathan@gmail.com